Acesion Pharma ApS
http://www.acesionpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acesion Pharma ApS
Acesion Seeks Partner For First-In-Class AF Program Following Phase II Success
Having reached proof-of-concept for its first-in-class SK ion channel inhibitor for atrial fibrillation, the Danish firm is on the hunt for a licensee as it moves its attention to its preclinical program for sinus rhythm maintenance.
Venture Funding Deals: Innovent Sets Financing Record In China
The firm’s $260m Series D is the largest ever for biopharma in China and one of the biggest of the year worldwide; other notable financings go to Biohaven, Kymab and Magenta. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October through early December.
Execs On The Move, May 2016
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Atrial Fibrillation Agents: Better Drugs For The Arrhythmic Heart
Improvements in targeting the sources of aberrant cardiac rhythms may open the heart up to new therapies. In this issue, we profile four start-ups focused on developing treatments for AF and other arrhythimas: Acesion Pharma, ChanRx, Milestone Pharmaceuticals and Serodus.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice